MX2022010539A - Combinacion que comprende alpelisib y acido 6-(2,4-diclorofenil)-5 -[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro -7h-benzo[7]anulen-2-carboxilico. - Google Patents

Combinacion que comprende alpelisib y acido 6-(2,4-diclorofenil)-5 -[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro -7h-benzo[7]anulen-2-carboxilico.

Info

Publication number
MX2022010539A
MX2022010539A MX2022010539A MX2022010539A MX2022010539A MX 2022010539 A MX2022010539 A MX 2022010539A MX 2022010539 A MX2022010539 A MX 2022010539A MX 2022010539 A MX2022010539 A MX 2022010539A MX 2022010539 A MX2022010539 A MX 2022010539A
Authority
MX
Mexico
Prior art keywords
combination
alpelisib
annulene
oxyphenyl
fluoropropyl
Prior art date
Application number
MX2022010539A
Other languages
English (en)
Inventor
Monsif Bouaboula
Zhuyan Guo
Maysoun Shomali
Fangxian Sun
Stéphane Poirier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2022010539A publication Critical patent/MX2022010539A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En el presente documento se proporcionan una combinación de alpelisib y de ácido 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropr opil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anulen-2-ca rboxílico o una sal farmacéuticamente aceptable del mismo, una composición farmacéutica que contiene una combinación de este tipo, y los usos terapéuticos de los mismos, en particular para el tratamiento del cáncer, incluyendo cáncer de mama.
MX2022010539A 2020-02-27 2021-02-26 Combinacion que comprende alpelisib y acido 6-(2,4-diclorofenil)-5 -[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro -7h-benzo[7]anulen-2-carboxilico. MX2022010539A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20305190 2020-02-27
PCT/EP2021/054815 WO2021170793A1 (en) 2020-02-27 2021-02-26 Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid

Publications (1)

Publication Number Publication Date
MX2022010539A true MX2022010539A (es) 2022-09-21

Family

ID=69784379

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010539A MX2022010539A (es) 2020-02-27 2021-02-26 Combinacion que comprende alpelisib y acido 6-(2,4-diclorofenil)-5 -[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro -7h-benzo[7]anulen-2-carboxilico.

Country Status (13)

Country Link
US (1) US20230089371A1 (es)
EP (1) EP4110326B1 (es)
JP (1) JP2023516951A (es)
KR (1) KR20220146473A (es)
CN (1) CN115209893B (es)
AR (1) AR121589A1 (es)
AU (1) AU2021227007A1 (es)
BR (1) BR112022015972A2 (es)
CA (1) CA3168936A1 (es)
IL (1) IL295807A (es)
MX (1) MX2022010539A (es)
TW (1) TW202146007A (es)
WO (1) WO2021170793A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884079B (zh) * 2016-02-15 2021-03-05 赛诺菲 作为雌激素受体调节剂的6，7-二氢-5h-苯并[7]轮烯衍生物
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN111386113A (zh) * 2017-12-01 2020-07-07 诺华股份有限公司 包含lsz102和阿培利司的药物组合

Also Published As

Publication number Publication date
JP2023516951A (ja) 2023-04-21
AR121589A1 (es) 2022-06-22
AU2021227007A1 (en) 2022-10-20
KR20220146473A (ko) 2022-11-01
IL295807A (en) 2022-10-01
EP4110326B1 (en) 2024-01-31
CN115209893A (zh) 2022-10-18
BR112022015972A2 (pt) 2022-10-11
TW202146007A (zh) 2021-12-16
CN115209893B (zh) 2024-08-30
CA3168936A1 (en) 2021-09-02
WO2021170793A1 (en) 2021-09-02
EP4110326A1 (en) 2023-01-04
US20230089371A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
PH12020500091A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
EP1546136A4 (en) BENZOPYRANE DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES, INCLUDING IMIDAZOLE, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
CY1105608T1 (el) Φαρμακευτικες συνθεσεις παραγωγου του λευκοχρυσου
EP1820503A3 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
MX2009001130A (es) Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos.
MY143599A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
TNSN01009A1 (fr) (+) - 6 - [amino - (6 - chloro - pyridine - 3 - yl) - (3 - methyl - 3h - imidazole - 4 - yl) - methyl ] - 4 - ( 3 - chloro-phenyl) -1- cyclopropylmethyl - 1h - quinoleine - 2 - one, procede pour sa preparation et composition la contenant
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
DE602004014163D1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
BR112021022216A2 (pt) Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
TR200001906T2 (tr) Koks-Inhibitörleri olarak 2,3-ikameli indol bileşikleri.
SE9903997D0 (sv) New compounds
ATE280168T1 (de) Verbindung mit wachstumshormon-freisetzenden eigenschaften
MX2022008342A (es) Metodos para tratar afecciones relacionadas con el receptor de s1p1.
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
MX2022010539A (es) Combinacion que comprende alpelisib y acido 6-(2,4-diclorofenil)-5 -[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro -7h-benzo[7]anulen-2-carboxilico.
MX2023006020A (es) Combinacion que comprende abemaciclib y acido 6-(2,4-diclorofenil)-5-[4-[(3s)- 1-(3-fluoropropil)pirrolidin-3-il ]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico.
MY122477A (en) Sertraline oral concentrate
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
ATE448796T1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
WO2001074809A1 (fr) Derives d'acylthiophene et leur utilisation en tant que medicaments